Diagnostics Pipeline: 2024 Trends in FDA Approvals
In vitro diagnostic products approved by the U.S. Food and Drug Administration in 2024 show a continued move toward rapid and point-of-care tests
Keep up to date on new and emerging diagnostic tests, testing trends and opportunities, and disruptive technologies
In vitro diagnostic products approved by the U.S. Food and Drug Administration in 2024 show a continued move toward rapid and point-of-care tests
From - Diagnostic Testing & Emerging Technologies
Women who do not meet breast cancer genetic testing criteria have a similar number of cancer-associated mutations as women who do meet the criteria…
From - Diagnostic Testing & Emerging Technologies
Screening the entire U.S. blood supply for Zika virus may not be worth the $42 million price tag. Fifteen months of screening all…
From - Diagnostic Testing & Emerging Technologies
A genetic risk score (GRS) may identify patients at highest risk for developing atrial fibrillation (AF), according to a study published…
From - Diagnostic Testing & Emerging Technologies
The FY 2018 omnibus appropriations bill, passed by Congress in late March, included a little noticed provision that could ultimately bring significant changes to the laboratory industry…
From - Diagnostic Testing & Emerging Technologies
Raw data from direct-to-consumer (DTC) genetic tests have an "alarmingly high" false-positive rate, according to a study published…